These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38655202)

  • 21. Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern.
    Kitchin D; Richardson SI; van der Mescht MA; Motlou T; Mzindle N; Moyo-Gwete T; Makhado Z; Ayres F; Manamela NP; Spencer H; Lambson B; Oosthuysen B; Kaldine H; du Pisanie M; Mennen M; Skelem S; Williams N; Ntusi NAB; Burgers WA; Gray GG; Bekker LG; Boswell MT; Rossouw TM; Ueckermann V; Moore PL
    Cell Rep Med; 2022 Mar; 3(3):100535. PubMed ID: 35474744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.
    Tan CS; Collier AY; Yu J; Liu J; Chandrashekar A; McMahan K; Jacob-Dolan C; He X; Roy V; Hauser BM; Munt JE; Mallory ML; Mattocks M; Powers JM; Meganck RM; Rowe M; Hemond R; Bondzie EA; Jaegle KH; Baric RS; Schmidt AG; Alter G; Le Gars M; Sadoff J; Barouch DH
    JAMA Netw Open; 2022 Aug; 5(8):e2226335. PubMed ID: 35947380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination.
    Geers D; Sablerolles RSG; van Baarle D; Kootstra NA; Rietdijk WJR; Schmitz KS; Gommers L; Bogers S; Nieuwkoop NJ; van Dijk LLA; van Haren E; Lafeber M; Dalm VASH; Goorhuis A; Postma DF; Visser LG; Huckriede ALW; Sette A; Grifoni A; de Swart RL; Koopmans MPG; van der Kuy PHM; GeurtsvanKessel CH; de Vries RD;
    iScience; 2023 Jan; 26(1):105753. PubMed ID: 36507223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
    He X; Chandrashekar A; Zahn R; Wegmann F; Yu J; Mercado NB; McMahan K; Martinot AJ; Piedra-Mora C; Beecy S; Ducat S; Chamanza R; Huber SR; van Heerden M; van der Fits L; Borducchi EN; Lifton M; Liu J; Nampanya F; Patel S; Peter L; Tostanoski LH; Pessaint L; Van Ry A; Finneyfrock B; Velasco J; Teow E; Brown R; Cook A; Andersen H; Lewis MG; Schuitemaker H; Barouch DH
    Cell; 2021 Jun; 184(13):3467-3473.e11. PubMed ID: 34133941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies.
    Iheanacho CO; Eze UIH
    Futur J Pharm Sci; 2022; 8(1):20. PubMed ID: 35368622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humans.
    Dari A; Jacqmin P; Iwaki Y; Neyens M; Le Gars M; Sadoff J; Hardt K; Ruiz-Guiñazú J; Pérez-Ruixo JJ
    CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1485-1498. PubMed ID: 37715342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).
    Khan K; Lustig G; Bernstein M; Archary D; Cele S; Karim F; Smith M; Ganga Y; Jule Z; Reedoy K; Miya Y; Mthabela N; Magula NP; Lessells R; de Oliveira T; Gosnell BI; Abdool Karim S; Garrett N; Hanekom W; Bekker LG; Gray G; Blackburn JM; Moosa MS; Sigal A;
    Clin Infect Dis; 2022 Aug; 75(1):e857-e864. PubMed ID: 34893824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.
    Keeton R; Richardson SI; Moyo-Gwete T; Hermanus T; Tincho MB; Benede N; Manamela NP; Baguma R; Makhado Z; Ngomti A; Motlou T; Mennen M; Chinhoyi L; Skelem S; Maboreke H; Doolabh D; Iranzadeh A; Otter AD; Brooks T; Noursadeghi M; Moon JC; Grifoni A; Weiskopf D; Sette A; Blackburn J; Hsiao NY; Williamson C; Riou C; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Moore PL; Burgers WA
    Cell Host Microbe; 2021 Nov; 29(11):1611-1619.e5. PubMed ID: 34688376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.
    Roozendaal R; Solforosi L; Stieh DJ; Serroyen J; Straetemans R; Dari A; Boulton M; Wegmann F; Rosendahl Huber SK; van der Lubbe JEM; Hendriks J; Le Gars M; Dekking L; Czapska-Casey DN; Guimera N; Janssen S; Tete S; Chandrashekar A; Mercado NB; Yu J; Koudstaal W; Perez-Ruixo JJ; Sadoff J; Barouch DH; Schuitemaker H; Zahn R
    Nat Commun; 2021 Oct; 12(1):5877. PubMed ID: 34620860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study.
    Hyun H; Choi MJ; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Choi JY; Lee YJ; Lee HW; Kim SS; Kim B; Song JY
    J Korean Med Sci; 2022 Jul; 37(27):e210. PubMed ID: 35818701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.
    Barouch DH; Stephenson KE; Sadoff J; Yu J; Chang A; Gebre M; McMahan K; Liu J; Chandrashekar A; Patel S; Le Gars M; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H
    medRxiv; 2021 Jul; ():. PubMed ID: 34268527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study.
    Prather AA; Dutcher EG; Robinson J; Lin J; Blackburn E; Hecht FM; Mason AE; Fromer E; Merino B; Frazier R; O'Bryan J; Drury S; Epel ES
    Sci Rep; 2023 May; 13(1):6505. PubMed ID: 37160978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants.
    Padhiar NH; Liu JB; Wang X; Wang XL; Bodnar BH; Khan S; Wang P; Khan AI; Luo JJ; Hu WH; Ho WZ
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques.
    Yu J; Tostanoski LH; Mercado NB; McMahan K; Liu J; Jacob-Dolan C; Chandrashekar A; Atyeo C; Martinez DR; Anioke T; Bondzie EA; Chang A; Gardner S; Giffin VM; Hope DL; Nampanya F; Nkolola J; Patel S; Sanborn O; Sellers D; Wan H; Hayes T; Bauer K; Pessaint L; Valentin D; Flinchbaugh Z; Brown R; Cook A; Bueno-Wilkerson D; Teow E; Andersen H; Lewis MG; Martinot AJ; Baric RS; Alter G; Wegmann F; Zahn R; Schuitemaker H; Barouch DH
    Nature; 2021 Aug; 596(7872):423-427. PubMed ID: 34161961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach.
    Dari A; Boulton M; Neyens M; Le Gars M; Valenzuela B; Shukarev G; Cárdenas V; Ruiz-Guiñazú J; Sadoff J; Hoetelmans RMW; Ruixo JJP
    Clin Pharmacol Ther; 2023 Feb; 113(2):380-389. PubMed ID: 36377532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.
    Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F
    J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
    Solforosi L; Kuipers H; Jongeneelen M; Rosendahl Huber SK; van der Lubbe JEM; Dekking L; Czapska-Casey DN; Izquierdo Gil A; Baert MRM; Drijver J; Vaneman J; van Huizen E; Choi Y; Vreugdenhil J; Kroos S; de Wilde AH; Kourkouta E; Custers J; van der Vlugt R; Veldman D; Huizingh J; Kaszas K; Dalebout TJ; Myeni SK; Kikkert M; Snijder EJ; Barouch DH; Böszörményi KP; Stammes MA; Kondova I; Verschoor EJ; Verstrepen BE; Koopman G; Mooij P; Bogers WMJM; van Heerden M; Muchene L; Tolboom JTBM; Roozendaal R; Brandenburg B; Schuitemaker H; Wegmann F; Zahn RC
    J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33909009
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.